Fibrous dysplasia of the spine is very rarely observed. We reported a case of a 57-year-old woman, who presented with neck and bilateral shoulder pain with histologically confirmed fibrous dysplasia, involving the first and second thoracic vertebrae. Clinical and radiological findings were not specific for fibrous dysplasia. The histological biopsy was required for a confirmed diagnosis. Endocrine and metabolic evaluations are required to rule out diseases such as hyperthyroidism, Cushing syndrome and osteomalacia. Fibrous dyplasia can be managed by appropriate medical and surgical treatments based on the patient's neurological status and symptoms. Our patient was given intravenous pamidronate 60 mg/day for 3 days. After 9 months, her initial symptoms were improved, but computed tomography scan of the thoracic spine showed no change of the lesions.
INTRODUCTION
Fibrous dysplasia (FD), originally described by Lichtenstein in 1938 8) and Jaffe in 1942 9) , is a disorder of bone development of unknown etiology, in which cancellous bone is replaced with fibrous tissue resulting in bone expansion. The disease is often subcategorized based on the number of bones involved. Monostotic lesions involve only one bone, whereas polyostotic involve many bones. The spine is affected in only 7-24% of cases, and fibrous dysplasia of the spine is very rarely observed without disease elsewhere in the body 1, 14) . Fibrous dysplasia of vertebrae in monostotic form has rarely been reported in the literature 2, 11, 15) . Polyostotic fibrous dysplasia involving the spine is relatively common. However, polyostotic form of fibrous dysplasia with isolated thoracic spinal localization has not been reported yet 12, 18, 19) . We reported a case of a 57-yearold woman, with a histologically confirmed fibrous dysplasia, involving the T1, T2 vertebrae.
CASE REPORT
A 57-year-old woman complained of neck pain and bilateral shoulder pain of 20 days duration. She visited a local hospital doctor, and magnetic resonance imaging (MRI) of cervical spine showed spine metastasis. Positron emission tomography scan showed a hypermetabolic second thoracic spine and mild and focal hypermetabolism in the right breast. She was referred to our institution on 13 th March, 2014. On admission, there was no evidence of neurologic deficit. Abnormal skin pigmentation was absent. Physical examination revealed no Spurling or Lhermitte's sign. Enhanced MRI of the cervical spine revealed a metastasis in the vertebral body, both lamina and spinous process of the first thoracic spine, vertebral body, and left lamina of the second thoracic spine (Fig. 1, 3 ). Whole body bone scan revealed a focally active bony lesion in the first thoracic spine and otherwise, no active lesion (Fig. 2) . Breast sonography and mammography showed negative findings.
Tumor markers (AFP, CEA, CA 19-9, CA125, CYFRA 21-1, NSE) were normal. Ultrasound guided bone biopsy was performed in the spinous process of the second thoracic spine. Histologic examination revealed irregular thin trabeculae of wooven bone with bland-looking spindle cell stroma, suggestive of fibrous dysplasia (Fig. 4) .
Surgical treatment was not performed, due to minor symptoms, no increasing pain, and no neurological symptoms. The patient was given intravenous pamidronate 60 mg/day for 3 days and discharged. After 6 months, she was admitted our institution, and was given intravenous pamidronate 60 mg/day for 3 days again. Thoracic computed tomography scan showed no change of fibrous dysplasia involving bodies and posterior elements of the first and second thoracic spine (Fig. 5) . However, previous neck pain and bilateral shoulder pain were improved. Three months later, the cervical magnetic resonance imaging scan showed no change of fibrous dysplasia involving bodies and posterior elements of the first and second thoracic spine.
DISCUSSION
Fibrous dysplasia is a benign intramedullary fibro-osseus lesion characterized by the replacement of bone and marrow with poorly organized spicules of immature bone in fibrous connective tissue 8, 9) . This clinical entity is divided into 2 types: single-bone involvement (the monostotic type) and multiple-bone involvement (the polyostotic type). Monostotic form is more frequent (75-80%) than the polystotic form. The polyostotic form has a McCune-Albright syndrome (multiple bone lesions with or without cafe-au-lait spots and with endocrine dysfunction including precocious puberty, hyperthyroidism, acromegaly) and a Mazabraud syndrome (multiple bone lesion with soft tissue mycosomes) 1) . Fibrous dysplasia is typically asymptomatic and discovered incidentally. It rarely leads to neurologic deficit. Usually, the common symptom is a localized, painful swelling 13) . In some cases, it may cause a pathologic fracture 2, 11, 15) . Because of the scarcity of this disorder and symptom, it is hard to know the exact frequency, but fibrous dysplasia represents approximately 2.5% of all bone neoplasms and 7% of benign bone neoplasms. Malignant transformation occurs with a frequency of 0.5% in monostotic form but it may rise to 4% in the McCune-Albright syndrome 1) . The etiology of fibrous dysplasia has been linked to an activating mutation in the GNAS1 gene located at 20q13.2-13.3 that encodes the alpha subunit of stimulatory Gs protein.
Due to this mutation, adenyl cylase stimulation, overproduction of cyclic AMP, and overexpression of the c-fos protein leads to abnormally differentiated osteoblastic cell that overproduce interleukin-6, which causes osteoclast overactivity and osteolysis in the fibrous tissue and bone 5, 16, 20) . The most common involvements of the disease are long bones such as femur, tibia and cranial, facial, ribs and pelvis while vertebral involvement is rare. The spine involvement occurs in 1.4% to 5.5% of fibrous dysplasia lesions. Although monostotic fibrous dysplasia occurs more frequently (corresponding to 70% of cases) than the polyostotic form (23%) 1) , spinal involvement is mostly seen in the polyostotic form and is very unusal in the monostotic variety 1, 14) . There have been a few case reports of monostotic fibrous dysplasia involving only one vertebra. Oba et al. 11) managed fibrous dysplasia involving the 10 th vertebra alone by tumor resection followed by bone grafting with hydroxyapatite material. Arazi et al. 2) treated fibrous dysplasia located in Th6 with a transthoracic approach and used costal graft and interbody fusion after enbloc resection.
Spinal involvement is frequently seen in the polyostotic form, but isolated thoracic spine involvement has not been previously reported. This was the first polyostotic fibrous dysplasia case involving the thoracic spine alone. In the study of Leet et al. 7) , spinal involvement was observed in 63% of the cases with accompany lesions in the pelvis, rib or skull by bone scanning. Arantes et al. 1) 's report indicated that polyostotic fibrous dysplasia has a vertebral involvement rate of 7-24%.
An endocrine and metabolic evaluation is necessary after confirmatory diagnosis by histologic examinations.
The reported treatment of fibrous dysplasia in the spine varies widely from surgical resection to biopsy and observation. There have been various options including calcitonin, denosumab, bisphosphonate (pamidronate, zoledronate) and mithramycin and operative treatment including currettage, fixation, fusion, and bone grafting. Each treatment options are available according to patient's symptom and neurologic status.
Surgical indications for fibrous dysplasia include spinal instability and confirming the diagnosis and neurologic deficit. Przybylski et al. 15) conducted posterior fusion and instrumentation combined with anterior strut graft and 360° spinal fusion after resecting the tumor in fibrous dysplasia located in thorax. Their patient had kyphotic deformation and neurological progression. Wu et al. 17) treated thoracic fibrous dysplasia by decompression surgery combined with vertebroplasty and posterior fusion.
Some studies reported that the pain and radiologic lesions associated with fibrous dysplasia lesions were successfully treated with bisphosphonates. Liens et al. 10) reported 9 patients treated with intravenous pamidronate (60 mg per day over 3 days every six months), who were followed for 18-48 months. Radiologic changes were seen in 4 patients with cortical thickening, and refilling of osteolytic lesions. Chapurlat et al. 6 ) treated 58 patients with fibrous dysplasia using intravenous pamidronate 180 mg every 6 months and reported that intravenous pamidronate improves the radiologic aspect in 50% patients with fibrous dysplasia. Antiresorptive agents such as biphophonates can be used due to high density of osteoclasts and evidence of bone resorption in fibrous dysplasia lesions. However, Boyce et al. 4) reported that alendronate had effect on reduction in the bone resorption marker but no significant effect on serum osteocalcin, pain or functional parameters. In another study, Boyce et al. 3) present the case of a 9-year-old boy with severe fibrous dysplasia who was treated with denosumab. Over 7 months of treatment, the pain was mar-kedly reduced and bone turnover markers were reduced. Randomized control studies and further clinical trials are necessary to establish medical treatment of fibrous dysplasia.
CONCLUSION
In conclusion, we presented a case of polyostotic fibrous dysplasia involving thoracic spine with symptom of neck pain, bilateral shoulder pain mimicking a metastatic lesion or infectious lesion. Fibrous dysplasia often has vague clinical and radiological findings. Histological biopsy is therefore required. Endocrine and metabolic evaluation should be performed to exclude hyperthyroidism, Cushing syndrome, and osteomalacia. Fibrous dyplasia can be managed by appropriate medical and surgical treatment based on the patient's neurological status and symptoms. We treated the patient with intravenous pamidronate 60 mg/day for 3 days. After 9 months, her initial symptoms were improved, but the computed tomography scan of the thoracic spine showed no change in the lesions.
